Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Canadian team describes cardioprotective activity of AAA-135

Nov. 10, 1998

Eplerenone effectively treats hypertension and aldosterone-induced damage in CV organs

Nov. 9, 1998

NK-26588: new inhibitor of iNOS produced by Streptomyces sp.

Nov. 9, 1998

Further evidence of the potential utility of BO-653 in restenosis

Nov. 9, 1998

Novel endothelin antagonists claimed for cardiovascular, cerebrovascular and other disorders

Nov. 6, 1998

Ribozyme oligonucleotides against apo(a) as novel therapeutic strategy for cardiovascular diseases

Nov. 5, 1998

Merck's new ET receptor antagonists

Nov. 5, 1998

Optimal dosing regimen for 5G1.1-SC in heart attack under evaluation in phase I trial

Nov. 4, 1998

Involvement of central A3 receptors in blood pressure regulation

Nov. 3, 1998

Suntory describes new series for cardio- and cerebrovascular and peripheral circulatory disorders

Nov. 3, 1998

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...